CAJ | 학술논문

目的：评价利妥昔单克隆抗体联合CHOP方案治疗高龄非霍奇金淋巴瘤（ NHL）患者的疗效。方法将2010年10月至2013年10月入院的76例老年NHL患者随机分为两组；CHOP方案组36例，利妥昔单克隆抗体联合 CHOP 方案组40例。采用回顾分析方法，比较两组患者6个疗程后的临床疗效并记录其不良反应。结果 CHOP组患者的完全缓解率为25.00％，总有效率为55.56％；利妥昔单克隆抗体联合 CHOP方案组分别为45.00％，77.50％，两组总有效率差异具有统计学意义（χ2＝4.133，P＜0.05）；两组治疗方案毒副反应发生率差异无统计学意义（ P＞0.05）；两组治疗前的IgA、lgG、IgM 水平均无统计学差异（ P＞0.05），治疗后水平均较治疗前显著下降（ P＜0.05），且两组间无统计学差异（ P＞0.05）。结论利妥昔单克隆抗体联合CHOP方案治疗高龄NHL临床疗效较好且不良反应未增加，但还应实时监测患者的免疫功能。
목적：평개리타석단극륭항체연합CHOP방안치료고령비곽기금림파류（ NHL）환자적료효。방법장2010년10월지2013년10월입원적76례노년NHL환자수궤분위량조；CHOP방안조36례，리타석단극륭항체연합 CHOP 방안조40례。채용회고분석방법，비교량조환자6개료정후적림상료효병기록기불량반응。결과 CHOP조환자적완전완해솔위25.00％，총유효솔위55.56％；리타석단극륭항체연합 CHOP방안조분별위45.00％，77.50％，량조총유효솔차이구유통계학의의（χ2＝4.133，P＜0.05）；량조치료방안독부반응발생솔차이무통계학의의（ P＞0.05）；량조치료전적IgA、lgG、IgM 수평균무통계학차이（ P＞0.05），치료후수평균교치료전현저하강（ P＜0.05），차량조간무통계학차이（ P＞0.05）。결론리타석단극륭항체연합CHOP방안치료고령NHL림상료효교호차불량반응미증가，단환응실시감측환자적면역공능。
Objective To evaluate the clinical effect of Rituximab combined with CHOP scheme in the treatment of elderly patients with non Hodgkin's lymphoma ( NHL) .Methods Methods:76 cases of elderly patients with NHL from October 2010 to October 2013 were randomly divided into two groups:36 cases of CHOP group ,40 cases of Rituximab combined with CHOP scheme group .The clinical curative effect of two groups were compared after 6 courses of treatment and the adverse reaction was recorded .Results The complete remission rate of CHOP group was 25%, and the total effective rate was 55 .56%;while the complete remission rate in Rituximab combined with CHOP scheme group was 45.00%,and the total effective rate was 77.50%,the total effective rate between two groups had statistically significant difference(χ2=4.133,P=0.042).The treatment adverse reaction rate between two groups had no significant difference (P>0.05 ).There were no statistical differences of IgA , IgG, IgM levels between the two groups before treatment (P>0.05), and they were higher than those before treatment (P<0.05), but there were no significant differences between the two groups after treatment (P>0.05).Conclusions The clinical effect of Rituximab combined with CHOP scheme in the treatment of elderlypatients with NHL is good and adverse reactions do not in -crease.